1. Home
  2. BNR vs UNCY Comparison

BNR vs UNCY Comparison

Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$10.79

Market Cap

99.7M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$5.15

Market Cap

150.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
UNCY
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.7M
150.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BNR
UNCY
Price
$10.79
$5.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.67
AVG Volume (30 Days)
11.8K
680.7K
Earning Date
06-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$675,000.00
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.79
$3.72
52 Week High
$41.72
$8.74

Technical Indicators

Market Signals
Indicator
BNR
UNCY
Relative Strength Index (RSI) 52.67 47.30
Support Level $8.83 $4.81
Resistance Level $10.72 $5.86
Average True Range (ATR) 0.76 0.22
MACD -0.01 -0.01
Stochastic Oscillator 53.02 29.01

Price Performance

Historical Comparison
BNR
UNCY

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Share on Social Networks: